Patent application number | Description | Published |
20130344069 | Antigen Binding Proteins that Bind IGF1R - There is disclosed compositions and methods relating to or derived from anti-IGF1R antibodies. More specifically, there is disclosed fully human antibodies that bind IGF1R, IGF1R-binding fragments and derivatives of such antibodies, and IGF1R-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF1R related disorders or conditions, including various inflammatory disorders and various cancers. | 12-26-2013 |
20130344070 | Antigen Binding Proteins that Bind CCR2 - There is disclosed compositions and methods relating to or derived from anti-CCR2 antibodies. More specifically, there is disclosed fully human antibodies that bind CCR2, CCR2-binding fragments and derivatives of such antibodies, and CCR2-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having CCR2 related disorders or conditions. | 12-26-2013 |
20140120093 | Anti-Infective Binding Proteins that Bind AIP2 - There is disclosed compositions and methods relating to or derived from anti-AIP2 antibodies. More specifically, there is disclosed fully human antibodies that bind AIP2, AIP2-binding fragments and derivatives of such antibodies, and AIP2-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having AIP2 related disorders or conditions. There is also disclosed a method to treat | 05-01-2014 |
20140294827 | Fully Human Antibodies that Bind to VEGFR2 - There is disclosed compositions and methods relating to anti-VEGFR2 antibodies. More specifically, there is disclosed fully human antibodies that bind VEGFR2, VEGFR2-binding fragments and derivatives of such antibodies, and VEGFR2-binding polypeptides comprising such fragments. Further still, there is disclosed antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having various cancers. | 10-02-2014 |
Patent application number | Description | Published |
20080285495 | Systems and Methods for Communicating to a Disassociated Station in a Protected Network - Stations in standby mode in a wireless local area network (WLAN) become disassociated with their access point. In the event traffic is intended for the station in standby mode, a wakeup message needs to be communicated to the station. Typically, a wakeup message could be broadcast on a broadcast or multicast address, and when the station checks for broadcasts, the station can determine whether it needs to wake up. However, in a protected network, a disassociated station cannot decrypt messages from the access point without reassociating. However, the cost of reassociating in time and power can be significant, so reassociating should not be performed unless the station needs to wake up, leading to a vicious cycle as the station does not know it must wake up unless it can decrypt the message. To address this issue, in one embodiment the access points do not encrypt messages on a select multicast address, whereby messages such as wakeup message can be transmitted. In another embodiment, the messages are still encrypted. However, the identification of which station must wake up is encoded as the length of the encrypted payload. These methods allow a general message of communicating to disassociated stations in a protected WLAN environment. | 11-20-2008 |
20110081640 | Systems and Methods for Protecting Websites from Automated Processes Using Visually-Based Children's Cognitive Tests - Visually based children's cognitive tests can be used as a human challenge or Turing test to verify that a human and not an automated process is operating a particular system, such as purchasing tickets, downloading files, accessing a database, or requesting a reprieve from an anti-spam system. Several different visually oriented cognitive tests can be used as a human challenge, for example, selecting one object in a group of object that is different, selecting an object from a group of objects which is most similar to a given object, selecting two objects in a group of objects that are most similar, finding a given object in a scene, counting the number of instances of an object in a scheme and object based analogies. | 04-07-2011 |
Patent application number | Description | Published |
20140266383 | Self-Activating Adjustable Power Limiter - A fast response time, self-activating, adjustable threshold limiter including a limiting element LE, a first coupling element CE | 09-18-2014 |
20150091650 | Amplifier with Variable Feedback Impedance - A variable feedback impedance is presented capable of providing high linearity (e.g. as represented by 1P2 and 1P3) and high linear range (e.g. as represented by P1dB) when used in a feedback path of an RF amplifier in the presence of high voltage amplitudes. | 04-02-2015 |
20150162901 | Integrated Switch and Limiter Circuit - A fast response time, self-activating, adjustable threshold limiter including a limiting element LE, a first coupling element CE | 06-11-2015 |
20150372525 | Capacitance Discharge Limiter - A capacitance discharge limiter in which a DC transition protection circuit is provided in a circuit that includes a discharge circuit (which may be a power limiter) between a source and a receiver, with a capacitor situated between the source and the discharge circuit. The DC transition protection circuit is coupled to a reference voltage and to the control voltage input of the discharge circuit, and also between the capacitor and the discharge circuit at a node. The DC transition protection circuit detects the existence of an excess DC or low frequency (typically less than about 1 MHz) voltage potential at the node caused by charge on the capacitor, and regulates the control voltage so as to enable the discharge circuit to discharge the capacitor to protect the receiver. | 12-24-2015 |
Patent application number | Description | Published |
20150263676 | INTEGRATOR FOR CLASS D AUDIO AMPLIFIER - An apparatus includes voltage-to-current conversion circuitry comprising a first voltage-to-current converter and a second voltage-to-current converter. The apparatus also includes a capacitor coupled to the first voltage-to-current converter and to the second voltage-to-current converter. | 09-17-2015 |
20150381119 | AUDIO SWITCHING AMPLIFIER - A switching amplifier includes a compensation circuit to compensate for DC offset in the amplifier, to enhance operation of the switching amplifier. The compensation circuit may comprise a SAR ADC, where the DAC element can be used to provide a compensation voltage. The switching amplifier may further include a PWM modulator configured to avoid cross-talk to further enhance operation of the switching amplifier. | 12-31-2015 |
20160056763 | SWITCHED-CAPACITOR RC OSCILLATOR - An RC oscillator includes a first capacitive element and a second capacitive element and a comparator having a first input, a second input, and an output for outputting an oscillating signal. The oscillator further includes an integrator having a first input, a second input coupled to a reference voltage source, and an output coupled to the second input of the comparator. The oscillator further includes a switch circuit configured to provide a voltage of the first capacitive element to the first input of the comparator in a cycle and a voltage of the second capacitive element to the first input of the comparator in a subsequent cycle. The integrator is configured to sample and to hold the voltage of the second capacitive element continuously in the cycle. | 02-25-2016 |
20160065134 | ASYMMETRIC H-BRIDGE IN A CLASS D POWER AMPLIFIER - Disclosed is an amplifier circuit having an output stage that includes an H-bridge circuit. The H-bridge circuit includes sense resistors on one side of the circuit. A current detection circuit can produce an output indicative of current flow through a load based on voltages across the sense resistors. | 03-03-2016 |
Patent application number | Description | Published |
20090262481 | APPARATUS, SYSTEM, AND METHOD FOR ELECTROSTATIC DISCHARGE PROTECTION - An apparatus, system, and method provide electrostatic discharge (ESD) protection in electronic devices by guiding electrostatic charges to a ground through ESD channels within electrical insulation sheet. The ESD channels are positioned within the electrical insulation sheet to provide electrical paths to ground having a lower impedance than electrical paths to protected areas covered by the electrical insulation sheet. Accordingly, an ESD follows the path of least resistance safely to ground rather than to a critical component within the electronic device. In the exemplary embodiment, the ESD channels are openings in a dome contact layer of a keypad where the openings are positioned over one or more ground areas of a printed circuit board (PCB) and the insulting material of the dome contact layer covers areas of the PCB that are protected from ESD. By implementing dedicated GPIO lines, grounded metal domes cover the signal pads in the target discharge area to protected the GPIO lines from ESD. Device components are protected from ESD without additional ports or insulation. | 10-22-2009 |
20120021707 | APPARATUS AND METHOD FOR ADJUSTMENT OF TRANSMITTER POWER IN A SYSTEM - Certain aspects of the present disclosure propose methods for determining power level of one or more transmitters based on a power level of a primary transmitter when the transmitters are located in close proximity of each other. The power levels may be determined such that a combined power of all the transmitters is compliant with regulatory radio frequency (RF) safety requirements. For certain aspects, power level of the lower priority transmitters may be determined utilizing one or more look-up tables. For another aspect, power level of the lower priority transmitters may be calculated using an algorithm based on the power level of the priority transmitter. In aspects, the power level of lower priority transmitters and the time duration for which the transmitters are active may be selected dynamically so that the time averaged power of the transmitters for a defined period of time falls below the RF exposure limit. | 01-26-2012 |
20140273819 | NEAR-FIELD EQUIVALENT SOURCE REPRESENTATION FOR SAR ESTIMATION - Efficient techniques for estimating specific absorption rate (SAR) for wireless devices. In an aspect, electric and/or magnetic field measurements are made over a two-dimensional (2D) surface in the proximity of a wireless device. The field measurements are used to generate a near-field equivalent source representation of the wireless device. Specific absorption rate over, e.g., a 1 g/10 g mass may then be calculated by performing electromagnetic simulations using the near-field equivalent source representation. In an aspect, an elementary dipole array may be used to generate the near-field equivalent source representation from the field measurements. | 09-18-2014 |
20140274190 | REAL-TIME EXPOSURE ASSESSMENT - Efficient techniques for determining compliance of a wireless device with radio-frequency (RF) exposure standards and regulations. In an aspect, two-dimensional surface scans of a device are determined and stored in a memory during a certification phase. Each scan corresponds to a basis surface scan wherein only one transmitter and one antenna of the device are active. During real-time operation, the basis surface scans corresponding to the real-time active transmitters and antennas of the device are retrieved. The retrieved scans are processed according to the real-time operating parameters to determine an estimated RF exposure metric, e.g., a peak specific absorption rate (SAR). The transmit power levels of the device may be adjusted in real time to ensure compliance of the estimated RF exposure metric with applicable standards and regulations. | 09-18-2014 |
20150177302 | COMPLIANCE ASSESSMENT OF HUMAN EXPOSURE FROM WIRELESS ELECTRIC VEHICLE CHARGING SYSTEM - This disclosure provides systems, methods and apparatus for assessing electromagnetic exposure. In one aspect an apparatus is provided. The apparatus includes at least a first circuit configured to calculate electromagnetic exposure of at least a portion of at least one human in proximity to a wireless electric vehicle charging system. The portion of the at least one human is modeled by at least one homogeneous phantom model having dielectric properties that are representative of human tissue. The apparatus further includes at least a second circuit configured to scale the calculated electromagnetic exposure to simulate an electromagnetic exposure based on an inhomogeneous anatomical model of the portion of the at least one human. | 06-25-2015 |
20150197155 | CONTROLLING CURRENT FLOW PATH IN WIRELESS ELECTRIC VEHICLE CHARGING SYSTEMS FOR MITIGATING RF RADIATED EMISSIONS - This disclosure provides systems, methods and apparatus for mitigating electromagnetic radiation emissions. In one aspect, a power transfer device of a wireless electric vehicle charging (WEVC) system is provided. The power transfer device includes a ferrite material and at least one electrically conductive coil. The ferrite material and the at least one coil are configured to wirelessly transfer energy either from or to a second power transfer device of the WEVC system. The power transfer device further includes at least one shield comprising a plurality of electrically conducting regions and one or more electrically insulating regions. The plurality of electrically conducting regions and one or more electrically insulating regions are configured to mitigate electromagnetic radiation emissions from the WEVC system that do not contribute to the wireless power transfer between the at least one electrically conductive coil and the second power transfer device. | 07-16-2015 |
Patent application number | Description | Published |
20100056582 | Modulators of LXR - Compounds of the invention, such as compounds of formula (I): | 03-04-2010 |
20100069367 | LXR and FXR Modulators - Compounds of the invention are disclosed, such as compounds of formulae LX-LXIV, and pharmaceutically acceptable salts, isomers, or prodrugs thereof, which are useful as modulators of the activity of liver X receptors (LXR) and Farnesoid X receptors (FXR), where R | 03-18-2010 |
20100075964 | IMIDAZOLE BASED LXR MODULATORS - Compounds of the invention, such as compounds of Formulae IIa, IIb, IIc or IId, and pharmaceutically acceptable salts, isomers, and prodrugs thereof, are useful as modulators of the activity of liver X receptors, where R | 03-25-2010 |
20100331295 | MODULATORS OF LXR - Compounds of the invention, such as compounds of Formulae Ia, Ib, Ic, or Id and pharmaceutically acceptable salts, isomers, and prodrugs thereof, which are useful as modulators of the activity of liver X receptors, where R1, R2, R21, R3, and G are defined herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed. | 12-30-2010 |
20140038964 | IMIDAZOLE BASED LXR MODULATORS - Methods of using compounds of the invention, such as compounds of Formulae IIa, IIb, IIc, or IId | 02-06-2014 |
Patent application number | Description | Published |
20090075996 | HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS - The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated TPO activity, particularly diseases or disorders that involve thrombocytopenia. | 03-19-2009 |
20100298295 | 2-BIPHENYLAMINO-4-AMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS - The invention provides novel pyrimidine derivatives of formula (1) and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin-like growth factor (IGF-1R) or anaplastic lymphoma kinase (ALK). | 11-25-2010 |
20110112063 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS - The invention provides novel pyrimidine derivatives of formula I and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin-like growth factor (IGF-IR) or analplastic lymphoma kinase (ALK). | 05-12-2011 |
20110112096 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS - The invention provides novel pyrimidine derivatives of formula (I) and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin-like growth factor (IGF-IR) or analplastic lymphoma kinase (ALK). | 05-12-2011 |
20110257154 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS - The invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof. | 10-20-2011 |
20120165310 | ETHER DERIVATIVES OF BICYCLIC HETEROARYLS - The invention relates to compounds of formula I, | 06-28-2012 |
20120289501 | Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls - The invention relates to new derivatives of formula I, wherein the substituents are as defined in the specification; to processes for the preparation of such derivatives; pharmaceutical compositions comprising such derivatives; such derivatives as a medicament; such derivatives for the treatment of a proliferative disease. | 11-15-2012 |
20130005748 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS - The invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof. | 01-03-2013 |
20130310361 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS - The invention provides novel pyrimidine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin-like growth factor (IGF-1R) or analplastic lymphoma kinase (ALK). | 11-21-2013 |
20130338152 | FLUOROPHENYL BICYCLIC HETEROARYL COMPOUNDS - The present invention provides a compound the invention, and its use as a IGF-1R inhibitor. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition. | 12-19-2013 |
20150105390 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS - The invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof. | 04-16-2015 |
20150197505 | Compounds and Compositions for Modulating EGFR Activity - The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating EGFR activity, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated EGFR activity. | 07-16-2015 |
Patent application number | Description | Published |
20140139209 | MAGNETIC AUTOMATIC TESTING EQUIPMENT (ATE) MEMORY TESTER - Several novel features pertain to an automatic testing equipment (ATE) memory tester that includes a load board, a projected-field electromagnet, a positioning mechanism and a memory tester. The load board is for coupling to a die package that includes a magnetoresistive random access memory (MRAM) having several cells, where each cell includes a magnetic tunnel junction (MTJ). The projected-field electromagnet is for applying a portion of a magnetic field across the MRAM. The portion of the magnetic field may be substantially uniform. The positioning mechanism is coupled to the electromagnet and the load board, and is configured to position the electromagnet vertically about (above/below) the die package when the die package is coupled to the load board. The memory tester is coupled to the load board. The memory tester is for testing the MRAM when the substantially uniform portion of the magnetic field is applied across the MRAM. | 05-22-2014 |
20140254251 | MAGNETIC AUTOMATIC TEST EQUIPMENT (ATE) MEMORY TESTER DEVICE AND METHOD EMPLOYING TEMPERATURE CONTROL - In a particular embodiment, a method includes controlling a temperature within a chamber while applying a magnetic field. A device including a memory array is located in the chamber. The method includes applying a magnetic field to the memory array and testing the memory array during application of the magnetic field to the memory array at a target temperature. | 09-11-2014 |
20150179281 | DATA RETENTION ERROR DETECTION SYSTEM - A particular method includes selecting a threshold data retention time of a magnetic tunnel junction (MTJ) memory cell. A pinned layer of the MTJ memory cell has a first direction of magnetization, and a free layer of the MTJ memory cell has a second direction of magnetization. An external magnetic field that has a third direction of magnetization that is opposite to the second direction of magnetization is applied to the MTJ memory cell. A strength of the external magnetic field is determined based on the threshold data retention time. Subsequent to applying the external magnetic field, a read operation is performed on the MTJ memory cell to determine a logic value of the MTJ memory cell. The method further includes determining whether the MTJ memory cell is subject to a data retention error corresponding to the threshold data retention time based on the logic value. | 06-25-2015 |
20150204856 | METHODS TO DETERMINE FLUID FILTRATION RATES THROUGH MAMMALIAN LUMINAL ORGANS - Methods to determine fluid filtration rates through mammalian luminal organs. In one method, the method comprises the steps of positioning a segment of a mammalian luminal organ within a device, the device configured to prevent axial flow conditions through a lumen of the segment from a first end of the segment to an opposite second end of the segment, obtaining a first segment measurement at a first time, obtaining a second segment measurement at a second time, and determining a rate of fluid filtration through a wall of the segment based upon a difference between the first segment measurement and the second segment measurement and a difference in time between the first time and the second time. | 07-23-2015 |
20160067031 | METHODS AND USES OF MEDIASTINAL PLEURA TISSUE FOR VARIOUS STENT AND OTHER MEDICAL APPLICATIONS - Methods, products and uses of or relating to biological tissues for various stent and other medical applications are disclosed. In an exemplary embodiment of a method of processing a tissue of the present disclosure, the method comprises the steps of acquiring a tissue comprising at least a portion of parietal pleura, selecting a sample of mediastinal pleura tissue from the parietal pleura tissue, and fixing the sample of mediastinal pleura tissue using a fixative, resulting in a fixed sample. Furthermore, in an embodiment of a tissue product of the present disclosure, the tissue product comprises a frame configured to retain mediastinal pleura tissue thereon and such tissue coupled to the frame. | 03-10-2016 |
Patent application number | Description | Published |
20110015438 | PROCESS FOR THE PREPARATION OF INTERMEDIATES RELATED TOTHE 5-HT2C AGONIST (R)-8-CHLORO-1-METHYL-2,3,4,5,-TETRAHYDRO-1H-3-BENZAZEPINE - The present invention provides processes and intermediates useful in the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, a serotonin (5-HT) receptor agonist that is useful in the treatment or prophylaxis of, for example, central nervous system disorders, such as obesity. | 01-20-2011 |
20120142967 | PROCESSES FOR THE PREPARATION OF 5-HT2C RECEPTOR AGONISTS - The present invention relates to processes and intermediates useful in the preparation of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (lorcaserin), a serotonin (5-HT) receptor modulator that is useful in the treatment of, for example, central nervous system disorders, such as obesity. | 06-07-2012 |
20150210625 | PROCESSES FOR THE PREPARATION OF 5-HT2C RECEPTOR AGONISTS - The present invention relates to processes and intermediates useful in the preparation of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (lorcaserin), a serotonin (5-HT) receptor modulator that is useful in the treatment of, for example, central nervous system disorders, such as obesity. | 07-30-2015 |